CAPITOLO 8: DISCUSSIONI E CONCLUSIONI
8.2 Conclusioni
Gli analoghi della SRIF possono interferire con il processo di retinopatia a vari livelli, incluso il controllo dell’espressione dei fattori proangiogenici. Durante questo lavoro di tesi è stato dimostrato che gli analoghi della SRIF con elevata specificità per sst2 regolano l’angiogenesi
retinica e che i loro effetti implicano una modulazione del sistema del VEGF. Potrebbe quindi essere possibile una loro azione benefica sulla retinopatia diabetica dato che i fattori di crescita locali peggiorano tale patologia, sebbene non possano comunque essere esclusi a priori effetti antiangiogenici diretti di questi analoghi.
Letteratura citata
Abbott N.J. Revest, PA, Romero, IA. Astrocyte-endothelial interaction:physiology and pathology. Neuropathol Appl Neurobiol (1992) 18:424–33
Adamis A.P., Miller, J.W., Bernal, M.T., D’Amico, D.J., Folkman, J., Yeo, T.K., Yeo, K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. (1994)118: 445–450.
Adams R.L., Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer. (2005)92:1493- 1498.
Aiello L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., Pasquale, L.R., Thieme, H., Iwamoto, M.A., Park, J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. (1994a)331: 1480–1487
Aiello L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.;Shah, S.T.; Pasquale, L.; Thieme, H.; Iwamoto, M.A.; Park, J.E.;H.V., N.; Aiello, L.M.; Ferrara, N. and King, G.L. New Eng. J. Med. (1994b) 331: 1480-1487.
Aiello L.P., Bursell SE, Clermont A et al. : Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective -isoform-selective inhibitor. Diabetes (1997) 46: 1473 -1780.
Aiello L.P., Gardner, T.W., et al. Diabetic retinopathy. Diabetes Car. (1998) 21: 143–156. Allen J.P., Hathway G.J., Clarke N.J., Jowett M.I., Topps S., Kendrick K.M., Humphrey P.P.,
Wilkinson L.S. and Emson P.C. Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur. J. Neurosci. (2003)17: 1881-1895.
Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 48:257– 293
Antonelli-Orlidge, A., Saunders, K.B., Smith, S.R., D’Amore, P.A. An activated form of transforming growth factor is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci (1989) 86: 4544-48.
Arden G.B. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br. J. Ophthalmol. (2001)85: 366–370
Asahara T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275: 964–967.
Ashton N., B. Ward, G. Serpell, Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia, Br. J. Ophthalmol. (1954) 38: 397– 432.
Ashton N. Retinal vascularization in health and disease. Am. J. Ophthalmol. (1957)44: 7–17. Ashton N. The blood–retinal barrier and vaso-glial relationships in retinal disease. Trans.
Ophthal. Soc. UK (1965) 85:199–230
Ashton N., Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture, Am. J. Ophthalmol. (1966) 62: 412–435. Aydede H., Seda Vatansever H, Erhan Y, Ilkgül O. Effects of ocreotide on intestinal mucosa
Aymerich, M.S., Alberdi, E.M., Martinez, A., Becerra, S.P. Evidence for pigment epithelium- derived factor receptors in the neural retina. Invest. Ophthalmol. Vis. Sci. (2001) 42: 3287–3293
Ayoub G.S. and Matthews G. Substance P modulates calcium current in retinal bipolar neurons. Vis. Neurosci. (1992) 8: 539-544.
Bainbridge JW, Mistry A, Trasher AJ, Ali RR: Gene theraphy for ocular angiogenesis. Clin. Sci. (2003) 104: 561 -575.
Barber, A.J. Prog Neuropsychopharmacol Biol Psychiatry,27, 283-290. Martin, P.M.; Roon, P.; Van Ells, T.K.; Ganapathy, V. and Smith, S.B. (2004) Invest. Ophthalmol. Vis. Sci. (2003) 45: 3330-3336.
Barleon, B., Sozzani, S., Zhou, D., Weich, H.A., Mantovani, A., Marme, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996)87: 3336–3343.
Barnett, P.. Somatostatin and somatostatin receptor physiology. Endocrine (2003) 20: 255– 264.
Barnstable, C.J. and Tombran-Tink, J. Prog. Retin. Eye Res. (2004) 23: 561-577.
Barra, A.; Blacher, S.; Vandendriessche, T.; Ponten, A.; Eriksson, U.; Plate, K.H.; Foidart, J.M.; Schaper, W.; Charnock-Jones, D.S.;Hicklin, D.J.; Herbert, J.M.; Collen, D. and Persico, M.G. Nat. Med. (2001) 7: 575-583.
Barreca, A., Cariola, G., Ponzani, P., Arvigo, M., Foppiani, L., Giordano, G. & Minuto, F. Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clinical Endocrinology. (1995) 42: 161–167.
Barrie, R., Woltering, E.A., Harjarizadeh, H., Mueller, C., Ure, T. & Fletcher, W.S. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. Journal of Surgical Research. (1993)55: 446–450.
Bass R. T., Buckwalter B. L., Patel B. P., et alIdentification and characterization of novel somatostatin antagonists. Mol. Pharmacol. (1996) 50: 709–715.
Battegay, E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. (1995) 73: 333–346.
Benelli, R., Morini, M., Carrozzino, F., Ferrari, N., Minghelli, S., Santi, L., Cassatella, M., Noonan, D.M., Albini, A. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. (2002) 16: 267–269.
Bensaid, M., Tahiri-Jouti, N., Cambillau, C., Vigurie, N., Colas, B., Vidal, C., Tauber, J.P., Esteve, J.P., Susini, C. & Vaysse, N. Basic fibroblast growth factor induces proliferation of a rat pancreatic cancer cell line. Inhibition by somatostatin. International Journal of Cancer. (1992) 50: 796–799.
Ben-Shlomo A, Pichurin O, Barshop NJ, et al. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol. (2007)21:2565-2578
Bigiani A., Petrucci C., Ghiaroni V., Dal Monte M., Cozzi A., Kreienkamp H.J., Richter D. and Bagnoli P. Functional correlates of somatostatin receptor 2 over-expression in the retina of mice with genetic deletion of somatostatin receptor 1. Brain Res. (2004)1025: 177-185.
Blaauwgeers, H.G., Holtkamp, G.M., Rutten, H., Witmer, A.N., Koolwijk, P., Partanen, T.A., Alitalo, K., Kroon, M.E., Kijlstra, A., van Hinsbergh, V.W., Schlingemann, R.O. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am. J. Pathol. (1999)155: 421–428.
Booth CE, Kirkup AJ, Hicks GA, Humphrey PP, Grundy D. Somatostatin sst(2) receptor- mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology. (2001)121:358-369.
Borras T: Recent developments in ocular gene therapy. Exp. Eye Res. (2003) 76: 643 -652. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of
protein utilizing the principle of protein-dye binding. Anal Biochem. (1976)72:248- 254.
Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J. And Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973)179: 77–79
Brecha N.C. Peptide and peptide receptor expression and function in the vertebrate retina. In: The visual neurosciences. Chalupa L.M. and Werner J.S. (eds). The MIT Press. Cambridge (MA). (2003):334-354.
Breier, G., Albrecht, U., Sterrer, S., Risau, W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. (1992)114: 521–532.
Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol (2001)119:198–207
Broderick, C, Duncan, L, Taylor, N, Dick, AD. IFN-gamma and LPS-mediated IL-10- dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci (2000) 41:2613–22
Brownlee, M. Nature (2001) 414: 813-820.
Bumcrot D, Manoharan M, Koteliansky V, Sah DW RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol (2006) 2:711–719
Buscail L, Delesque N, Esteve J, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. (1994)91: 2315- 2319
Buscail L, Esteve J-P, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. (1995)92: 1580-1584
Campochiaro, P.A., Soloway, P., Ryan, S.J., Miller, J.W. The pathogenesis of choroidal neovascularization in patients with agerelated macular degeneration. Mol. Vis. (1999) 5: 34–39.
Campochiaro, P.A. Retinal and choroidal neovascularization. J. Cell. Physiol. (2000) 184: 301–310.
Cao, Y., Linden, P., Shima, D., Browne, F., Folkman, J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J. Clin. Invest. (1996)98: 2507–2511.
Cao, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.H., Claesson-Welsh, L., Alitalo, K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA (1998)95: 14389–14394.
Cao, Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell. Biol. (2001) 33: 357–369.
Capone A Jr., Diaz-Rohena R, Sternberg P Jr., Mandell B, Lambert HM, Lopez PF Diode- laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol. (1993)116:444–450
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D,
Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996)380:435–439
Carmeliet P. Angiogenesis in health and disease. Nat Med (2003) 9: 653–660.
Carmeliet, P., Collen, D. Vascular development and disorders: molecular analysis and pathogenic insights. Kidney Int. (1998)53: 1519–1549.
Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature. (2000) 407: 249– 257.
Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.; Dewerchin, M.; Noel, A.; Stalmans, I. (2001)
Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscali L, Cordelier P. Characterization of the bystander effect of somatostatin receprot sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum. Gene Ther. (2005) 16:1175-93
Cascinu, S., Del Ferro, E., Ligi, M., Staccioli, M.P., Giordani, P., Catalano, V., Agostinelli, R., Muretto, P. & Catalano, G. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Investigation. (2001) 19: 8–12.
Casini G., Dal Monte M., Petrucci C., Gambellini G., Grouselle D., Allen J.P., Kreienkamp H.J., Richter D., Epelbaum J. and Bagnoli P. Altered morphology of rod bipolar cell axonal terminals in the retinas of mice carrying genetic deletion of somatostatin subtype receptor 1 or 2. Eur. J. Neurosci. (2004)19: 43-54.
Casini G, Catalani E, Dal Monte M, Bagnoli P. Functional aspectes of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retina disease. Histol Histopathol. (2005)20:615-632.
Cervia D, Nunn C, Bagnoli P. Multiple signalling transduction mechanisms differentially coupled to somatostatin receptor subtypes: a current view. Curr Enz Inhib. (2005)1:265-279.
Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: A current view. Mol Cell Endocrinol. (2008a)286:112-122.
Cervia D, Martini D, Ristori C, et al. Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J Neurochem. (2008b)106:2224-2235
Chader, G.J. PEDF: raising both hopes and questions in controlling angiogenesis. Proc. Natl. Acad. Sci USA. (2001) 98: 2122–2124.
Chang-Ling T, Baxter L, Afzal A et al. : Hematopoietic stem cells provide repair functions after laser-induced Bruch’s membrane rupture model of choroidal neovascularization. Am. J. Pathol. (2006) 168: 1031 -1044.
Chegini, N., & Guy, J. Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann NY Acad Sci (1993c)692: 230– 242.
Chu Y, Hughes S, Chan-Ling T. Differentiation and migration of astrocyte precursor cells and astrocytes in human fetal retina: relevance to optic nerve coloboma. FASEB J (2001) 15:2013–2015
Clauss, M.,Weich, H., Breier, G., Knies, U., R. ockl, W., Waltenberger, J., Risau, W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. (1996)271: 17629–17634
Conway, E.M., Collen, D., Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovas. Res. (2001) 49: 507–521.
Cooper ME, Vranes D, Youssef S, et al: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 48:2229–39
Cordelier P, Esteve JP, Bousquet C, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A. (1997)94:9343-9348
Cristiani R., Fontanesi G., Casini G., Petrucci C., Viollet C. and Bagnoli P. Expression of somatostatin subtype 1 receptor in the rabbit retina. Invest. Ophthalmol. Vis. Sci. (2000) 41: 3191-3199.
Cristiani R., Petrucci C., Dal Monte M. and Bagnoli P. Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res. (2002)936: 1-14.
Crocker, D.J., Murad, T.M., Geer, J.C. Role of the pericyte in wound healing. An ultrastructural study. Exp. Mol. Pathol. (1970)13: 51–65.
Cunha-Vaz, J.G. The blood–retinal barriers. Doc. Ophthalmol (1976) 41: 287–327
D’Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res. (1993)46:135-142.
Dal Monte M, Petrucci C, Vasilaki A, et al. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology. (2003)45:1080-1092.
Dal Monte M, Cammalleri M, Martini D, Casini G, Bagnoli P. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophtalmol Vis Sci. (2007)48:3480-3489 Danesi, R., & Del Tacca, M. The effects of the somatostatin analog octreotide on
angiogenesis in vitro. Metabolism (1996) 45: 49– 50.
Danesi, R., Agen, C., Benelli, U., Paolo, A. D., Nardini, D., Bocci, G., Basolo, F., Campagni, A., & Tacca, M. D. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res (1997)3: 265– 272. Dasgupta, P., Singh, A. T., & Mukherjee, R. Lipophilization of somatostatin analog RC-160
improves its bioactivity and stability. Pharm Res (1999)16: 1047– 1053.
Dasgupta P. Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. (2004) 102:61-85.
Davis MI, Wilson SH, Grant MB: The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm. Metab. Res. (2001) 33: 295 -299. Dawson, D.W., Volpert, O.V., Gillis, P., Crawford, S.E., Xu, H., Benedict, W., Bouck, N.P.
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (1999) 285: 245–248.
Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis. (2004)10:964-972. Djonov, V., Schmid, M., Tschanz, S.A., Burri, P.H. Intussusceptive angiogenesis: its role in
embryonic vascular network formation. Circ. Res. (2000) 86: 286–292.
Djonov, V., Baum, O., Burri, P.H. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res. (2003) 314: 107–117.
Dorrell, M.I., Aguilar, E., Friedlander, M. Retinal vascular development is mediated by endothelial filopodia, a pre-existing astrocytic template and specific R-cadherin adhesion. Invest. Ophthalmol. Vis. Sci. (2002) 43: 3500–3510.
Dorrell Michael I., Friedlander Martin. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Progress in Retinal and Eye Research (2006) 25: 277–295
Dumont, D.J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M., Alitalo, K. Cardiovascular failure in mouse embryos deficient in VEGF receptor- 3. Science (1998)282: 946–949.
Ellis, E.A.; Grant, M.B.; Murray, F.T.; Wachowski, M.B.;Guberski, D.L.; Kubilis, P.S. and Lutty, A. Free Radic.Biol. Med. (1998) 24: 111-120.
Ellis, E.A.; Guberski, D.L.; Somogyi-Mann, M. and Grant, M.B. Free Radic. Biol. Med. (2000) 28: 91-101.
Elner SG, Elner VM, Yoshida A, Dick RD, Brewer GJ. Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest Ophtalmol Vis Sci. (2005)46:299- 303.
El-Remessy, A.B.; Behzadian, M.A.; Abou-Mohamed, G.; Franklin, T.; Caldwell, R.W. and Caldwell, R.B. Am. J. Pathol. (2003a) 62: 1995-2004.
El-Remessy, A.B.; Abou-Mohamed, G.; Caldwell, R.W. and Caldwell, R.B. Invest. Ophthalmol. Vis. Sci. (2003b) 44: 3135-3143.
El-Remessy, A.B.; Bartoli, M.; Platt, D.H.; Fulton, D. and Caldwell, R.B. J. Cell Sci. (2005a) 118: 243-252.
El-Remessy, A.; Bartoli, M.; Platt, D.; Fulton, D. and Caldwell, R. J. Cell Sci. (2005b) 18: 243-252.
Epelbaum, J., Dournaud, P., Fodor, M., & Viollet, C. The neurobiology of somatostatin. Crit Rev Neurobiol (1994)8: 25– 44.
Eriksson, U., Alitalo, K. Structure, expression and receptorbinding properties of novel vascular endothelial growth factors. Curr. Top. Microbiol. Immunol. (1999) 237: 41– 57.
Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., Risau, W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell. Biol. (1998)140: 947–959.
Feindt, J., Becker, I., Blomer, U., Hugo, H.H., Mehdorn, H.M., Krisch, B., Mentlein, R. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J. Neurochem. (1995) 65: 1997–2005.
Feniuk W., Jarvie E., Luo J., and Humphrey P. P. A. Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide, CYN-154806. Neuropharmacology (2000) 39:1443–1450.
Ferjoux, G., Bousquet, C., Cordelier, P., Benali, N., Lopez, F., Rochaix, P., Buscail, L., & Susini, C. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris (2000) 94: 205– 210
Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol (1999) 237: 1–30.
Ferrara, N. Am. J. Physiol. Cell Physiol. (2001) 280: C1358-1366.
Ferrara, N Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 25:581–611
Ferrara, N., Houck, K., Jakeman, L., Leung, D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. (1992)13: 18–32. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan
KJ, Moore MW Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996)380:439–442
Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H.P., Nguyen, T.N., Peers, D., Chisholm, V., Hillan, K.J., Schwall, R.H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. (1998) 4: 336–340.
Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med (1971) 285: 1182– 1185.
Folkman, J., Ingber, D. Inhibition of angiogenesis. Semin. Cancer Biol. (1992) 3: 89–96. Fong, G.H., Rossant, J., Gertsenstein, M., Breitman, M.L. Role of the Flt-1 receptor tyrosine
kinase in regulating the assembly of vascular endothelium. Nature. (1995) 376: 66–70. Foos R., Kopelow S., Development of retinal vasculature in paranatal infants, Surv.
Forrester, J.V., Knott, R.M. The pathogenesis of diabetic retinopathy and cataract. In: Pickup J and Williams G Ed, Textbook of diabetes. Oxford, Blackwell Science (1997) 45:1- 19.
Fruttiger M, Calver AR, Kruger WH, Mudhar HS, Michalovich D, Takakura N, Nishikawa S, Richardson WD PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron (1996)17:1117–1131
Fruttiger Marcus. Development of the retinal vasculature. Angiogenesis (2007) 10:77–88 Fuh, G., Li, B., Crowley, C., Cunningham, B., Wells, J.A. Requirements for binding and
signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. (1998) 273: 11197–11204.
Gao, G., Ma, J. Tipping the balance for angiogenic disorders. Drug Discov. Today. (2002) 7: 171–172
Gardner Thomas W., Antonetti David A., Barber Alistair J., LaNoue Kathryn F., Levison Steven W., and The Penn State Retina Research Group: Diabetic Retinopathy: More Than Meets the Eye. Survey of ophtalmology (2002) 47, supplement 2: 253-262 Gerber, H.P., Condorelli, F., Park, J., Ferrara, N. Differential transcriptional regulation of the
two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. (1997)272: 23659–23667.
Gerber, H.P., Dixit, V., Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. (1998) 273: 13313–13316.
Geroski DH, Edelhauser HF: Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. (2000) 41: 961 -964 .
Ghirlanda, G., Di Leo, M.A., et al. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab. Rev. (1997) 13: 15–35.
Giardino, I., Brownlee, M. The biochemical basis of microvascular disease. In: Pickup JC, Williams G Ed. Textbook of diabetes.Oxford, Blackwell Science (1997) 42:1-16 Gilbert RE, Vranes D, Berka JL, et al: Vascular endothelial growth factor and its receptors in
control and diabetic rat eyes. Lab Invest (1998) 78:1017–27
Goldenberg-Cohen N, Dadon S, Avraham BC et al. Molecular and histological changes following central retinal artery occlusion in a mouse model. Exp Eye Res. (2008)87:327-333.
Graier, W.F.; Simecek, S.; Kukovetz, W.R. and Kostner, G.M. Diabetes, (1996) 45: 1386- 1395.
Graier, W.F.; Posch, K.; Wascher, T.C. and Kostner, G.M. Horm. Metab. Res. (1997) 29: 622-626.
Graier, W.F.; Posch, K.; Fleischhacker, E.; Wascher, T.C. and Kostner, G.M. Diabetes Res. Clin. Pract. (1999) 45: 153-160.
Grant MB, Caballero S, Millard WJ: Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Reg. Peptides (1993a) 48: 267 -278.
Grant, M.B., Mames, R. N., Fitzgerald, C., Ellis, E. A., Aboufriekha, M., & Guy, J. Insulin- like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia (1993b)36: 282– 291.
Grant M.B. and Caballero S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (2002a)38: 783-791.
Grant MB, May WS, Caballero S. et al.: Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat. Med. (2002b) 8: 607 - 612.
Grant, M.B., Mames, R. N., Fitzgerald, C., Ellis, E. A., Caballero, S., P. Dasgupta / Pharmacology & Therapeutics (2004)102: 61–85 81
Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol. (2005) 4:199-203.
Gu X, El Remessy AB, Brooks SE, Al Shabrawey M, Tsai NT, Caldwell RB Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol (2003) 285:C546–C554.
Guyton, A.C., Hall, J.E.: Textbook of Medical Physiology. Philadelphia, Saunders (2000) ed 10
Han, Y., Adams, A.J., et al. Multifocal electroretinogram and shortwavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch. Ophthalmol. (2004) 122: 1809–1815.
Hannon, J. P., Nunn, C., Stolz, B., Bruns, C., Weckbecker, G., Lewis, I., Troxler, T., Hurth, K., & Hoyer, D. Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci (2002a)18: 15– 27
Hannon J.P., Petrucci C., Fehlmann D., Viollet C., Epelbaum J. and Hoyer D. Somatostatin sst2 receptor knock-out mice: localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography. Neuropharmacology (2002b) 42: 396-413.
Hata, Y., Nakagawa, K., et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch. (1995) 426: 479–486.
Hathway GJ, Humphrey PP, Kendrick KM. Evidence that somatostatin sst2 receptors mediate striatal dopamine release. Br J Pharmacol. (1999)128:1346-1352.
Hayreh, S.S. The Cilio-Retinal Arteries. Br. J. Ophthalmol. (1963) 47: 71–89.
Hayry, P., Aavik, E. & Myllarniemi, M. Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury. Metabolism. (1996) 45 (Suppl. 1): 101–103
Hellstrom, A., Perruzzi, C., Ju, M., Engstrom, E., Hard, A., Liu, J., Albertsson-Wikland, K., Carlsson, B., Niklasson, A., Sjodell, L., LeRoith, D., Senger, D.R. & Smith, L.E.H. Low IGF-I suppress VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proceedings of the National Academy of Sciences of the United States of America. (2001) 98: 5804–5808.
Henkind, P., De Oliveira, L.F. Development of the retina vessels in the rat. Invest. Ophthalmol. Vis. Sci. (1967) 6: 520–523.
Higgins MD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res. (2002)74:553-559.
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci USA (1998) 95: 9349–9354.
Hirschi, K.K., D’Amore, P.A. Pericytes in the microvasculature. Cardiovasc. Res. (1996) 32: 687–698.
Hofland, L. J., van Hagen, P. M., & Lamberts, S. W. Functional role of somatostatin receptors in neuroendocrine and immune cells. Ann Med (1999)31(Suppl. 2): 23– 27.
Hogan, M.J., Feeney, L. The Ultrastructure of the Retinal Blood Vessels. I. The Large Vessels. J. Ultrastruct. Res. (1963) 39:10–28.
Holz, F.G., Sheraidah, G., Pauleikhoff, D., Bird, A.C. Analysis of lipid deposits extracted from human macular and peripheral Bruch’s membrane. Arch. Ophthalmol. (1994)112: 402–406.
Hoyer, D., Bell, G.I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humprey, P.P.A., O’Carroll, A.M., Patel, Y.C., Schonbrunn, A. & Taylor, J.E. Classification and nomenclature of somatostatin receptors. Trends in Pharmacological Science. (1995) 16: 86–88.
Hughes S, Chang-Ling T Roles of endothelial cell migration and apoptosis in vascular remodeling during development of the central nervous system. Microcirculation (2000) 7:317–333
Hyer, S.L. Growth hormone suppression in diabetic retinopathy. Diabetologia.(1987) 30: